The other thing people may have missed is the deltas/differences...

The other thing people may have missed is the deltas/differences between their submitted Amendment #2 and Amendment #3.

Amendment #3 reduces the terms of the warrant enabling Boustead to purchase GMVD shares for the first 5 years after listing. It was originally up to 7% of shares sold at an exercise price of 125% of the offering price. This has now been amended to 2% of total shares sold at an exercise price of 155% of the public offering price.

So Boustead's warrant is now for fewer shares at an increased premium...I'm still trying to work out what this means...also, the underwriting agreement Poorrundownhill correctly references has not been amended and re-submitted to reflect these new values...https://www.sec.gov/Archives/edgar/data/1760764/000121390020033625/ea129014ex1-1_gmedicalinno.htm